We Can Treat Erectile Dysfunction with "Acoustic Wave" Therapy - EPAT®
Those were the days…
The majority of men will experience a significant decline in sexual performance by the time they reach their 60’s and 70’s or even earlier. This does not have to be you. EPAT® is an FDA approved, scientifically proven treatment for Erectile Dysfunction and is now available for you.
Extracorporeal Pulse Activation
Treatment - EPAT®
EPAT® Is a Non-invasive Procedure That Uses Acoustic Pressure Waves
EPAT® is a non-invasive procedure that uses Acoustic Pressure Waves to stimulate cellular metabolism, enhance blood circulation and stimulate tissue regeneration creating new blood vessels in treated areas. EPAT® is sometimes referred to as “Shock Wave” or “Acoustic Wave” Therapy, but it actually stands for “Extracorporeal Pulse Activation Treatment.” EPAT® utilizes gentle acoustic pressure waves to enhance blood circulation, stimulate growth of new blood vessels and regenerate new tissue by creating micro-trauma and clearing out micro-plaque from the small vessels in the penis.
This both opens up the blood vessels in your penis and stimulates the growth of new blood vessels resulting in increased sensation in the penis, harder longer lasting erections, and it restores spontaneous sexual erections.
Gentle Acoustic Pressure Waves
Increases Blood Supply
Technology
and the FDA
EPAT® uses similar technology to a lithotripter, a medical device that uses acoustic waves to break up gallstones and kidney stones which has been widely used in the United States since 1982. In 2000, the FDA approved shockwave therapy for orthopedic use.
Advantages
- 100% SAFE
- Non-invasive
- No Down Time
- No Side Effects
- 15-20 minute per session
- Over 80% Patient Satisfaction
The New Viagra
Viagra was revolutionary when it came out in 1998 but now men are looking for a more permanent solution that is not drug dependent. EPAT® therapy has been used extensively in Europe for over 10-15 years but is relatively new to the U.S. for erectile dysfunction.
Acoustic pressure wave therapy or shockwave therapy has been shown to be very effective in treating Erectile Dysfunction with a satisfaction rate reported to be over 80%.
The Treatment
EPAT® treatment is non-invasive, similar to getting an ultrasound or sonagram. The procedure is not painful, but since it is being performed on the sensitive tissues of the penis, a local anesthetic numbing cream can be applied before treatment if needed. The low-intensity acoustic pressure waves are administered via a hand-held wand applicator that is moved over the area. Each treatment takes about 15-20 minutes and should be done twice per week for 4 to 6 weeks.
Research studies have shown the results to last 2 or more years. EPAT® can restore function similar to when you were in their 30’s or even 20’s. If you live a healthy life style and do not smoke, the results may essentially last a life time. In many cases, men come back for annual “tune-ups” to maintain theirsexual vitality.
Who is a suitable candidate?
- Men who have ED who would like to restore sexual function.
- Men who have ED and cannot tolerate the side effects of Viagra, Levitra, Cialis or other pills.
- Men in whom Viagra , Levitra or Cialis or other pills no longer work.
- Men who have Peyronie’s Disease (bent or curved penis.) The acoustic pressure waves can help break up the scar tissue and lessen or eliminate the curvature without surgery or painful injection therapy.
- All men. Men frequently experience a slowdown in sexual performance many years before they actually have Erectile Dysfunction. If you are experiencing any decline, you can benefit from EPAT® therapy.
ED Medical Studies
Can low-intensity extracorporeal shockwave therapy improve erectile dysfunction? A prospective, randomized, double-blind, placebo-controlled study. Olsen AB, Persiani M, Boie S, Hanna M, Lund L.; Scand J Urol. 2015;49(4):329-33. doi: 10.3109/21681805.2014.984326. Epub 2014 Dec 3. Link to Article
Extracorporeal shockwave therapy in the treatment of erectile dysfunction: a prospective, randomized, double-blinded, placebo controlled study. Yee CH, Chan ES, Hou SS, Ng CF. Int J Urol. 2014 Oct;21(10):1041-5. doi: 10.1111/iju.12506. Epub 2014 Jun 17. Link to Article
Shockwave treatment of erectile dysfunction. Ilan Gruenwald, Boaz Appel, Noam D. Kitrey, Yoram Vardi; Ther Adv Urol. 2013 Apr; 5(2): 95–99. Link to Article
Low intensity extracorporeal shockwave therapy for erectile dysfunction: a study in an Indian population. Srini VS, Reddy RK, Shultz T, Denes B. Can J Urol. 2015 Feb; 22(1):7614-22. Link to Article
A state-of-art review of low intensity extracorporeal shock wave therapy and lithotripter machines for the treatment of erectile dysfunction. Chung E, Wang J. Expert Rev Med Devices. 2017 Dec;14 (12):929-934. doi: 10.1080/17434440.2017.1403897. Epub 2017 Nov 29. Link to Article
Effects of Low-Intensity Extracorporeal Shockwave Therapy on Erectile Dysfunction: A Systematic Review and Meta-Analysis. Clavijo RI, Kohn TP, Kohn JR, Ramasamy R. J Sex Med. 2017 Jan;14(1):27-35. doi: 10.1016/j.jsxm.2016.11.001. Epub 2016 Dec 13. Link to Article
Low-intensity Extracorporeal Shock Wave Treatment Improves Erectile Function: A Systematic Review and Meta-analysis. Lu Z, Lin G, Reed-Maldonado A, Wang C, Lee YC, Lue TF. Eur Urol. 2017 Feb;71(2):223-233. doi: 10.1016/j.eururo.2016.05.050. Epub 2016 Jun 16. Link to Article
A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie’s disease. Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, Creta M, Mirone V. Eur Urol. 2009 Aug;56(2):363-9. doi: 10.1016/j.eururo.2009.05.012. Epub 2009 May 18. Link to Article.
Low-intensity Extracorporeal Shock Wave Therapy for Erectile Dysfunction: A Systematic Review and Meta-analysis. Man L, Li G. Urology. 2018 Sep;119:97-103. doi: 10.1016/j.urology.2017.09.011. Epub 2017 Sep 27. Link to Article
Clinical studies on low intensity extracorporeal shockwave therapy for erectile dysfunction: a systematic review and meta-analysis of randomised controlled trials. Sokolakis I, Hatzichristodoulou G. Int J Impot Res. 2019 Jan 21. doi: 10.1038/s41443-019-0117-z. Link to Article
